| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH |
From the Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Taipei, Taiwan, and Institution of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan.
Address reprint requests to: T’sang-T’ang Hsieh, MD, Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, 199 Tun Hwa North Road, Taipei 105, Taiwan, E-mail: tth3388{at}tpts1.seed.net.tw
Objective: To identify risk factors associated with placenta accreta in a large cohort study.
Methods: Data for this study came from the Taiwan Down Syndrome Screening Group, an ongoing project on feasibility of serum screening in an Asian population. Women who had serum screening for Down syndrome at 14–22 weeks’ gestation using alpha-fetoprotein (AFP) and free ß-hCG between January 1994 and June 1997, and delivered in the same institution, were included (n = 10,672). Those who had multiple gestations (n = 200), overt diabetes (n = 11), or fetal malformations (n = 101) were excluded. If a woman was involved more than once, one randomly selected pregnancy was included in the analysis (n = 9349). Twenty-eight pregnancies were complicated by placenta accreta, diagnosed by clinical presentation (n = 26) or histologic confirmation (n = 2). Multiple logistic regression with adjustment for potentially confounding variables was used to identify independent risk factors for placenta accreta.
Results: Women who had placenta previa (odds ratio [OR] 54.2; 95% confidence interval [CI] 17.8, 165.5) and second-trimester serum levels of AFP and free ß-hCG greater than 2.5 multiples of the median (OR 8.3; 95% CI 1.8, 39.3 and OR 3.9; 95% CI 1.5, 9.9, respectively), and were 35 years and older (OR 3.2; 95% CI 1.1, 9.4) were at increased risk of having placenta accreta.
Conclusion: Risk factors for placenta accreta include placenta previa, abnormally elevated second-trimester AFP and free ß-hCG levels, and advanced maternal age.
This article has been cited by other articles:
|
|
 |
|
  T.-H. Hung, C.-C. Hsieh, J.-J. Hsu, L.-M. Lo, T.-H. Chiu, and T.-T. Hsieh Risk Factors for Placental Abruption in an Asian Population Reproductive Sciences, January 1, 2007; 14(1): 59 - 65. [Abstract] [PDF]
|
|
|
|
 |
|
 D. DiGiacinto and A. Hildebrand Placenta Accreta. Radiol. Technol., November 1, 2006; 78(2): 165 - 168. [Full Text] [PDF]
|
|
|
|
|
|
T.-T. Hsieh, S.-F. Chen, W.-Y. Shau, C.-C. Hsieh, J.-J. Hsu, and T.-H. Hung The Impact of Interpregnancy Interval and Previous Preterm Birth on the Subsequent Risk of Preterm Birth Reproductive Sciences, April 1, 2005; 12(3): 202 - 207. [Abstract] [PDF]
|
|
|
|
 |
|
 J M Beuker, J J H M Erwich, and T Y Khong Is endomyometrial injury during termination of pregnancy or curettage following miscarriage the precursor to placenta accreta? J. Clin. Pathol., March 1, 2005; 58(3): 273 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Gielchinsky, D. Mankuta, N. Rojansky, N. Laufer, I. Gielchinsky, and Y. Ezra Perinatal Outcome of Pregnancies Complicated by Placenta Accreta Obstet. Gynecol., September 1, 2004; 104(3): 527 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. BUTLER, J. S. DASHE, and R. M. RAMUS Association Between Maternal Serum Alpha-Fetoprotein and Adverse Outcomes in Pregnancies With Placenta Previa Obstet. Gynecol., January 1, 2001; 97(1): 35 - 38. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
